rs114819130

Variant summary

Our verdict is Benign. The variant received -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2

The NM_001875.5(CPS1):​c.449G>A​(p.Gly150Glu) variant causes a missense change. The variant allele was found at a frequency of 0.0104 in 1,613,504 control chromosomes in the GnomAD database, including 118 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. G150G) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.0061 ( 4 hom., cov: 32)
Exomes 𝑓: 0.011 ( 114 hom. )

Consequence

CPS1
NM_001875.5 missense

Scores

1
9
8

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:1B:8

Conservation

PhyloP100: 3.65

Publications

15 publications found
Variant links:
Genes affected
CPS1 (HGNC:2323): (carbamoyl-phosphate synthase 1) The mitochondrial enzyme encoded by this gene catalyzes synthesis of carbamoyl phosphate from ammonia and bicarbonate. This reaction is the first committed step of the urea cycle, which is important in the removal of excess urea from cells. The encoded protein may also represent a core mitochondrial nucleoid protein. Three transcript variants encoding different isoforms have been found for this gene. The shortest isoform may not be localized to the mitochondrion. Mutations in this gene have been associated with carbamoyl phosphate synthetase deficiency, susceptibility to persistent pulmonary hypertension, and susceptibility to venoocclusive disease after bone marrow transplantation.[provided by RefSeq, May 2010]
CPS1 Gene-Disease associations (from GenCC):
  • carbamoyl phosphate synthetase I deficiency disease
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, G2P, Labcorp Genetics (formerly Invitae), ClinGen, Myriad Women’s Health

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -13 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.014847696).
BP6
Variant 2-210577488-G-A is Benign according to our data. Variant chr2-210577488-G-A is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 334013.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.00613 (933/152128) while in subpopulation NFE AF = 0.0101 (685/67998). AF 95% confidence interval is 0.00945. There are 4 homozygotes in GnomAd4. There are 420 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 4 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CPS1NM_001875.5 linkc.449G>A p.Gly150Glu missense_variant Exon 4 of 38 ENST00000233072.10 NP_001866.2 P31327-1A0A024R454Q6PEK7

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CPS1ENST00000233072.10 linkc.449G>A p.Gly150Glu missense_variant Exon 4 of 38 1 NM_001875.5 ENSP00000233072.5 P31327-1

Frequencies

GnomAD3 genomes
AF:
0.00614
AC:
933
AN:
152010
Hom.:
4
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00198
Gnomad AMI
AF:
0.0110
Gnomad AMR
AF:
0.00414
Gnomad ASJ
AF:
0.0104
Gnomad EAS
AF:
0.000193
Gnomad SAS
AF:
0.00499
Gnomad FIN
AF:
0.00255
Gnomad MID
AF:
0.00316
Gnomad NFE
AF:
0.0101
Gnomad OTH
AF:
0.00191
GnomAD2 exomes
AF:
0.00639
AC:
1605
AN:
251346
AF XY:
0.00635
show subpopulations
Gnomad AFR exome
AF:
0.00117
Gnomad AMR exome
AF:
0.00460
Gnomad ASJ exome
AF:
0.0111
Gnomad EAS exome
AF:
0.000109
Gnomad FIN exome
AF:
0.00383
Gnomad NFE exome
AF:
0.00937
Gnomad OTH exome
AF:
0.00816
GnomAD4 exome
AF:
0.0108
AC:
15828
AN:
1461376
Hom.:
114
Cov.:
31
AF XY:
0.0107
AC XY:
7780
AN XY:
727006
show subpopulations
African (AFR)
AF:
0.00149
AC:
50
AN:
33458
American (AMR)
AF:
0.00400
AC:
179
AN:
44718
Ashkenazi Jewish (ASJ)
AF:
0.0119
AC:
310
AN:
26126
East Asian (EAS)
AF:
0.0000252
AC:
1
AN:
39682
South Asian (SAS)
AF:
0.00424
AC:
366
AN:
86256
European-Finnish (FIN)
AF:
0.00404
AC:
216
AN:
53420
Middle Eastern (MID)
AF:
0.00225
AC:
13
AN:
5766
European-Non Finnish (NFE)
AF:
0.0126
AC:
14019
AN:
1111568
Other (OTH)
AF:
0.0112
AC:
674
AN:
60382
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.460
Heterozygous variant carriers
0
755
1510
2266
3021
3776
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
568
1136
1704
2272
2840
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00613
AC:
933
AN:
152128
Hom.:
4
Cov.:
32
AF XY:
0.00565
AC XY:
420
AN XY:
74350
show subpopulations
African (AFR)
AF:
0.00197
AC:
82
AN:
41528
American (AMR)
AF:
0.00413
AC:
63
AN:
15254
Ashkenazi Jewish (ASJ)
AF:
0.0104
AC:
36
AN:
3472
East Asian (EAS)
AF:
0.000194
AC:
1
AN:
5156
South Asian (SAS)
AF:
0.00499
AC:
24
AN:
4808
European-Finnish (FIN)
AF:
0.00255
AC:
27
AN:
10592
Middle Eastern (MID)
AF:
0.00340
AC:
1
AN:
294
European-Non Finnish (NFE)
AF:
0.0101
AC:
685
AN:
67998
Other (OTH)
AF:
0.00189
AC:
4
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.505
Heterozygous variant carriers
0
50
100
149
199
249
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00878
Hom.:
16
Bravo
AF:
0.00620
TwinsUK
AF:
0.0119
AC:
44
ALSPAC
AF:
0.0117
AC:
45
ESP6500AA
AF:
0.00159
AC:
7
ESP6500EA
AF:
0.0124
AC:
107
ExAC
AF:
0.00633
AC:
768
Asia WGS
AF:
0.00231
AC:
8
AN:
3478
EpiCase
AF:
0.0109
EpiControl
AF:
0.0103

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:8
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Congenital hyperammonemia, type I Benign:4
Jan 10, 2020
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. -

May 28, 2019
Mendelics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Uncertain:1Benign:2
Jun 15, 2017
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 08, 2021
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 18666241) -

Jan 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

CPS1: BS1, BS2 -

Inborn genetic diseases Benign:1
May 09, 2022
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

CPS1-related disorder Benign:1
Oct 12, 2021
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.28
BayesDel_addAF
Benign
-0.19
T
BayesDel_noAF
Uncertain
-0.040
CADD
Uncertain
24
DANN
Uncertain
0.99
DEOGEN2
Uncertain
0.68
D;.;D;D
Eigen
Benign
0.16
Eigen_PC
Benign
0.18
FATHMM_MKL
Uncertain
0.77
D
LIST_S2
Benign
0.81
T;D;D;D
MetaRNN
Benign
0.015
T;T;T;T
MetaSVM
Uncertain
0.46
D
MutationAssessor
Benign
1.1
.;.;L;.
PhyloP100
3.7
PrimateAI
Uncertain
0.62
T
PROVEAN
Pathogenic
-4.8
D;D;D;.
REVEL
Uncertain
0.63
Sift
Uncertain
0.0010
D;D;D;.
Sift4G
Uncertain
0.028
D;D;D;T
Polyphen
0.53
.;.;P;.
Vest4
0.76, 0.72, 0.71
MVP
0.95
MPC
0.58
ClinPred
0.063
T
GERP RS
4.4
Varity_R
0.88
gMVP
0.91
Mutation Taster
=93/7
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs114819130; hg19: chr2-211442212; COSMIC: COSV99028192; COSMIC: COSV99028192; API